A patient who is taking levothyroxine (Synthroid) texts a home care nurse and states "I feel very anxious and I have been having palpitations." Which of these responses should the nurse make to the patient?

A. Notify the provider of the patient's vital signs: The patient’s blood pressure is low (88/68 mm Hg), and administering additional nitroglycerin could worsen hypotension and lead to dizziness, syncope, or shock. Immediate provider notification is necessary before giving further doses.

B. Give nitroglycerin by translingual spray: Administering another form of nitroglycerin without addressing the hypotension risk could further lower blood pressure. Changing the route does not mitigate the danger of giving vasodilators to a hypotensive patient.

C. Administer 0.4 mg of nitroglycerin SL: Repeating the same SL dose while the patient is hypotensive may precipitate severe hypotension, syncope, or cardiovascular collapse. Further nitroglycerin must be held until guidance is obtained.

D. Administer 0.3 mg of nitroglycerin SL: Even a slightly lower dose could still dangerously reduce blood pressure. Administering additional nitroglycerin without provider approval is unsafe in the context of the patient’s current vital signs.

A. To treat hypertension and angina: Diltiazem is a calcium channel blocker that relaxes vascular smooth muscle and decreases myocardial oxygen demand, effectively lowering blood pressure and relieving angina. It is commonly prescribed for both conditions as a first-line therapy.

B. To prevent thromboembolism: Diltiazem does not have anticoagulant or antiplatelet effects and therefore does not prevent thromboembolic events. Other medications, such as warfarin or antiplatelet agents, are used for this purpose.

C. As an antiarrhythmic agent: Although diltiazem can slow atrioventricular conduction and may help control some arrhythmias, this is a secondary effect rather than its primary indication. Its main use remains in hypertension and angina management.

D. To manage heart failure: Diltiazem is generally not used for heart failure because negative inotropic effects can worsen cardiac output in patients with reduced ejection fraction. Other drug classes, such as ACE inhibitors or beta-blockers, are preferred for heart failure management.